| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 334 | 2024 | 2475 | 30.670 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 41 | 2024 | 1012 | 5.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 132 | 2024 | 16646 | 4.750 |
Why?
|
| Sulfonamides | 43 | 2024 | 1932 | 4.300 |
Why?
|
| Pyrazoles | 49 | 2024 | 1540 | 4.200 |
Why?
|
| Vidarabine | 51 | 2023 | 1383 | 4.080 |
Why?
|
| Neoplasm, Residual | 34 | 2024 | 1740 | 3.910 |
Why?
|
| Pyrimidines | 73 | 2024 | 3662 | 3.750 |
Why?
|
| Antineoplastic Agents | 111 | 2024 | 14631 | 3.640 |
Why?
|
| Adenine | 54 | 2024 | 669 | 3.440 |
Why?
|
| Piperidines | 55 | 2024 | 1087 | 3.040 |
Why?
|
| Rituximab | 67 | 2024 | 1588 | 2.940 |
Why?
|
| Protein Kinase Inhibitors | 57 | 2024 | 4961 | 2.760 |
Why?
|
| Antibodies, Monoclonal | 61 | 2019 | 4493 | 2.750 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 43 | 2014 | 879 | 2.350 |
Why?
|
| Aged | 279 | 2024 | 73451 | 2.130 |
Why?
|
| Cyclophosphamide | 46 | 2024 | 3244 | 2.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 30 | 2023 | 1545 | 2.100 |
Why?
|
| Immunotherapy, Adoptive | 17 | 2024 | 1839 | 2.000 |
Why?
|
| Humans | 498 | 2024 | 271550 | 1.950 |
Why?
|
| Aged, 80 and over | 173 | 2024 | 31066 | 1.930 |
Why?
|
| Middle Aged | 281 | 2024 | 90422 | 1.900 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 28 | 2024 | 2911 | 1.830 |
Why?
|
| Receptors, Antigen, B-Cell | 14 | 2022 | 174 | 1.810 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 14 | 2024 | 1739 | 1.790 |
Why?
|
| Lymphoma, B-Cell | 11 | 2022 | 934 | 1.710 |
Why?
|
| Immunoglobulin Heavy Chains | 14 | 2021 | 241 | 1.700 |
Why?
|
| Male | 286 | 2024 | 128724 | 1.610 |
Why?
|
| Tumor Lysis Syndrome | 4 | 2022 | 40 | 1.560 |
Why?
|
| Adult | 231 | 2024 | 82003 | 1.560 |
Why?
|
| Mutation | 42 | 2024 | 15918 | 1.560 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 33 | 2023 | 2634 | 1.560 |
Why?
|
| Antigens, CD19 | 9 | 2024 | 583 | 1.540 |
Why?
|
| Drug Resistance, Neoplasm | 41 | 2021 | 5407 | 1.490 |
Why?
|
| Antibodies, Neoplasm | 17 | 2011 | 274 | 1.480 |
Why?
|
| Disease-Free Survival | 73 | 2023 | 10258 | 1.470 |
Why?
|
| Immunotherapy | 22 | 2024 | 3547 | 1.460 |
Why?
|
| Female | 275 | 2024 | 149106 | 1.390 |
Why?
|
| Remission Induction | 53 | 2023 | 3653 | 1.380 |
Why?
|
| Leukemia, Myeloid, Acute | 39 | 2023 | 7262 | 1.360 |
Why?
|
| Treatment Outcome | 142 | 2024 | 33870 | 1.360 |
Why?
|
| Chromosomes, Human, Pair 17 | 15 | 2021 | 668 | 1.350 |
Why?
|
| Prognosis | 98 | 2024 | 22524 | 1.310 |
Why?
|
| Benzamides | 29 | 2022 | 1879 | 1.310 |
Why?
|
| Chromosome Deletion | 19 | 2024 | 1053 | 1.270 |
Why?
|
| Pyrazines | 10 | 2022 | 511 | 1.270 |
Why?
|
| Gene Expression Regulation, Leukemic | 19 | 2021 | 582 | 1.180 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2021 | 10370 | 1.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 37 | 2022 | 3396 | 1.170 |
Why?
|
| Immunoglobulin Variable Region | 10 | 2021 | 168 | 1.160 |
Why?
|
| Leukemia, B-Cell | 4 | 2017 | 114 | 1.090 |
Why?
|
| Flow Cytometry | 20 | 2019 | 3073 | 1.070 |
Why?
|
| Benzoates | 3 | 2018 | 128 | 1.060 |
Why?
|
| Myelodysplastic Syndromes | 27 | 2021 | 3148 | 1.050 |
Why?
|
| Smith-Magenis Syndrome | 6 | 2018 | 126 | 1.040 |
Why?
|
| Protein-Tyrosine Kinases | 30 | 2017 | 1839 | 1.040 |
Why?
|
| Salvage Therapy | 17 | 2021 | 2123 | 1.040 |
Why?
|
| beta 2-Microglobulin | 8 | 2015 | 189 | 1.030 |
Why?
|
| Antigens, CD20 | 9 | 2014 | 207 | 1.010 |
Why?
|
| Recurrence | 45 | 2024 | 4882 | 1.000 |
Why?
|
| Hydrazines | 3 | 2018 | 213 | 1.000 |
Why?
|
| Hematologic Neoplasms | 10 | 2023 | 1951 | 0.950 |
Why?
|
| Piperazines | 24 | 2019 | 2145 | 0.950 |
Why?
|
| Biomarkers, Tumor | 37 | 2021 | 10736 | 0.940 |
Why?
|
| Apoptosis | 41 | 2023 | 7783 | 0.940 |
Why?
|
| Follow-Up Studies | 58 | 2024 | 15247 | 0.930 |
Why?
|
| Neoplasm Proteins | 11 | 2022 | 3351 | 0.920 |
Why?
|
| Antibodies, Bispecific | 4 | 2022 | 277 | 0.910 |
Why?
|
| Cytarabine | 20 | 2021 | 2014 | 0.910 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 18 | 2023 | 288 | 0.900 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2019 | 2359 | 0.890 |
Why?
|
| STAT3 Transcription Factor | 10 | 2022 | 1137 | 0.880 |
Why?
|
| Purines | 10 | 2018 | 271 | 0.870 |
Why?
|
| Survival Rate | 50 | 2024 | 12528 | 0.860 |
Why?
|
| Leukemia, Hairy Cell | 4 | 2024 | 129 | 0.850 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2021 | 515 | 0.830 |
Why?
|
| Genetic Therapy | 9 | 2016 | 1713 | 0.800 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 2020 | 1067 | 0.790 |
Why?
|
| B-Lymphocytes | 17 | 2024 | 1427 | 0.780 |
Why?
|
| Bone Marrow | 17 | 2020 | 2439 | 0.760 |
Why?
|
| Thiazoles | 10 | 2019 | 723 | 0.750 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 2 | 2021 | 95 | 0.750 |
Why?
|
| Antigens, Neoplasm | 12 | 2020 | 1589 | 0.750 |
Why?
|
| CD40 Ligand | 6 | 2010 | 130 | 0.740 |
Why?
|
| Disease Progression | 34 | 2020 | 6857 | 0.730 |
Why?
|
| Thalidomide | 11 | 2016 | 595 | 0.730 |
Why?
|
| Medical Oncology | 2 | 2020 | 1462 | 0.720 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2024 | 332 | 0.700 |
Why?
|
| Vincristine | 17 | 2024 | 1582 | 0.700 |
Why?
|
| Alemtuzumab | 17 | 2011 | 213 | 0.690 |
Why?
|
| Kaplan-Meier Estimate | 36 | 2021 | 6264 | 0.690 |
Why?
|
| T-Lymphocytes | 21 | 2022 | 3942 | 0.690 |
Why?
|
| Dose-Response Relationship, Drug | 37 | 2021 | 5082 | 0.680 |
Why?
|
| Quinazolinones | 7 | 2018 | 52 | 0.680 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2022 | 3675 | 0.680 |
Why?
|
| Molecular Targeted Therapy | 8 | 2024 | 2390 | 0.670 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 11 | 2017 | 103 | 0.660 |
Why?
|
| Imatinib Mesylate | 23 | 2016 | 1690 | 0.650 |
Why?
|
| Immunologic Factors | 9 | 2021 | 669 | 0.650 |
Why?
|
| Thrombocytopenia | 9 | 2018 | 872 | 0.640 |
Why?
|
| Leukemia | 15 | 2020 | 1721 | 0.630 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 19 | 2023 | 7011 | 0.630 |
Why?
|
| Brain Edema | 1 | 2018 | 96 | 0.610 |
Why?
|
| Neoplasms, Second Primary | 13 | 2021 | 1387 | 0.610 |
Why?
|
| CD40 Antigens | 4 | 2012 | 106 | 0.610 |
Why?
|
| Clinical Trials as Topic | 17 | 2020 | 3850 | 0.580 |
Why?
|
| Drug Administration Schedule | 34 | 2020 | 3531 | 0.570 |
Why?
|
| Survival Analysis | 41 | 2021 | 9307 | 0.570 |
Why?
|
| Bendamustine Hydrochloride | 6 | 2017 | 122 | 0.560 |
Why?
|
| Chemokine CCL3 | 8 | 2017 | 65 | 0.560 |
Why?
|
| Chromosome Aberrations | 16 | 2021 | 2033 | 0.550 |
Why?
|
| Azacitidine | 9 | 2021 | 1219 | 0.550 |
Why?
|
| Stromal Cells | 13 | 2017 | 832 | 0.540 |
Why?
|
| Consensus | 1 | 2021 | 1115 | 0.540 |
Why?
|
| Nomograms | 4 | 2020 | 313 | 0.540 |
Why?
|
| Neoplasm Staging | 21 | 2021 | 14015 | 0.530 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 8 | 2021 | 629 | 0.530 |
Why?
|
| Lymphadenopathy | 1 | 2017 | 94 | 0.520 |
Why?
|
| Stem Cell Transplantation | 9 | 2022 | 1421 | 0.520 |
Why?
|
| Nitrogen Mustard Compounds | 2 | 2014 | 74 | 0.520 |
Why?
|
| Models, Biological | 10 | 2020 | 3207 | 0.510 |
Why?
|
| Philadelphia Chromosome | 13 | 2023 | 844 | 0.510 |
Why?
|
| Dexamethasone | 15 | 2024 | 1509 | 0.500 |
Why?
|
| Immunophenotyping | 11 | 2023 | 1731 | 0.490 |
Why?
|
| Chemokine CCL4 | 8 | 2017 | 68 | 0.490 |
Why?
|
| Fetal Blood | 3 | 2020 | 502 | 0.490 |
Why?
|
| Adolescent | 60 | 2024 | 32726 | 0.490 |
Why?
|
| Young Adult | 46 | 2024 | 22190 | 0.480 |
Why?
|
| Retrospective Studies | 55 | 2024 | 39818 | 0.480 |
Why?
|
| Neutropenia | 11 | 2023 | 1001 | 0.480 |
Why?
|
| Proportional Hazards Models | 19 | 2018 | 5099 | 0.470 |
Why?
|
| Antineoplastic Agents, Immunological | 9 | 2021 | 1335 | 0.460 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 7 | 2018 | 530 | 0.460 |
Why?
|
| MicroRNAs | 9 | 2024 | 2902 | 0.460 |
Why?
|
| Oxazoles | 3 | 2010 | 62 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 2422 | 0.450 |
Why?
|
| Antigens, CD | 13 | 2015 | 1429 | 0.440 |
Why?
|
| Dasatinib | 10 | 2018 | 881 | 0.440 |
Why?
|
| Leukemia, Promyelocytic, Acute | 4 | 2021 | 441 | 0.440 |
Why?
|
| Administration, Oral | 12 | 2019 | 1620 | 0.440 |
Why?
|
| Leukemia, Myeloid | 10 | 2008 | 994 | 0.430 |
Why?
|
| Fusion Proteins, bcr-abl | 10 | 2021 | 1144 | 0.420 |
Why?
|
| Pyridazines | 4 | 2018 | 319 | 0.420 |
Why?
|
| Signal Transduction | 28 | 2022 | 12134 | 0.420 |
Why?
|
| Drug Synergism | 12 | 2021 | 1360 | 0.420 |
Why?
|
| Arabinonucleosides | 6 | 2024 | 470 | 0.420 |
Why?
|
| Antigen-Presenting Cells | 2 | 2016 | 287 | 0.420 |
Why?
|
| Societies, Medical | 1 | 2019 | 1347 | 0.410 |
Why?
|
| Tumor Microenvironment | 8 | 2024 | 3022 | 0.410 |
Why?
|
| Idarubicin | 6 | 2017 | 459 | 0.400 |
Why?
|
| Enzyme Inhibitors | 9 | 2019 | 1950 | 0.400 |
Why?
|
| Doxorubicin | 14 | 2024 | 3144 | 0.390 |
Why?
|
| Lymphocytes | 11 | 2020 | 1279 | 0.390 |
Why?
|
| Transplantation, Homologous | 12 | 2020 | 3056 | 0.390 |
Why?
|
| Positron-Emission Tomography | 4 | 2017 | 2199 | 0.390 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2010 | 320 | 0.390 |
Why?
|
| Cell Proliferation | 16 | 2021 | 7259 | 0.380 |
Why?
|
| Receptor, Notch1 | 3 | 2022 | 219 | 0.370 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 3 | 2021 | 126 | 0.370 |
Why?
|
| Drug Approval | 2 | 2024 | 176 | 0.370 |
Why?
|
| Bone Marrow Cells | 8 | 2016 | 970 | 0.370 |
Why?
|
| Maximum Tolerated Dose | 14 | 2019 | 1322 | 0.370 |
Why?
|
| Tumor Cells, Cultured | 22 | 2021 | 5762 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2016 | 413 | 0.360 |
Why?
|
| Cancer Vaccines | 5 | 2024 | 754 | 0.360 |
Why?
|
| Combined Modality Therapy | 16 | 2021 | 9049 | 0.360 |
Why?
|
| Karyotype | 4 | 2019 | 237 | 0.350 |
Why?
|
| Therapies, Investigational | 2 | 2010 | 60 | 0.350 |
Why?
|
| Retreatment | 4 | 2017 | 448 | 0.350 |
Why?
|
| In Situ Hybridization, Fluorescence | 10 | 2021 | 2314 | 0.350 |
Why?
|
| Imidazoles | 4 | 2018 | 1058 | 0.350 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2010 | 79 | 0.340 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2010 | 66 | 0.340 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2020 | 1135 | 0.340 |
Why?
|
| Proteomics | 6 | 2024 | 1431 | 0.340 |
Why?
|
| Risk Factors | 32 | 2020 | 17982 | 0.340 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2010 | 78 | 0.330 |
Why?
|
| Lymphocyte Activation | 7 | 2016 | 1722 | 0.330 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2014 | 1350 | 0.320 |
Why?
|
| Multivariate Analysis | 14 | 2019 | 4337 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2010 | 252 | 0.320 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 215 | 0.310 |
Why?
|
| Cell Survival | 16 | 2019 | 3068 | 0.310 |
Why?
|
| Immunotherapy, Active | 2 | 2007 | 49 | 0.310 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 2 | 2019 | 48 | 0.310 |
Why?
|
| Lymphatic Diseases | 2 | 2013 | 130 | 0.310 |
Why?
|
| Leukemia, Prolymphocytic | 3 | 2019 | 54 | 0.300 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2021 | 749 | 0.290 |
Why?
|
| Coculture Techniques | 10 | 2022 | 631 | 0.290 |
Why?
|
| Lymphoma, Follicular | 3 | 2021 | 636 | 0.290 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2023 | 1092 | 0.290 |
Why?
|
| Isoquinolines | 3 | 2016 | 125 | 0.290 |
Why?
|
| Cytogenetic Analysis | 7 | 2017 | 574 | 0.270 |
Why?
|
| Withholding Treatment | 4 | 2016 | 155 | 0.270 |
Why?
|
| Lymphocyte Count | 4 | 2019 | 485 | 0.270 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2019 | 461 | 0.270 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2018 | 155 | 0.270 |
Why?
|
| Adenine Nucleotides | 4 | 2017 | 365 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2015 | 2616 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 4380 | 0.260 |
Why?
|
| Gossypol | 3 | 2012 | 28 | 0.260 |
Why?
|
| Chemokine CXCL13 | 2 | 2020 | 20 | 0.260 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 2 | 2016 | 57 | 0.260 |
Why?
|
| Asparaginase | 2 | 2024 | 198 | 0.260 |
Why?
|
| Time Factors | 19 | 2021 | 13077 | 0.260 |
Why?
|
| DNA Methylation | 9 | 2019 | 2761 | 0.250 |
Why?
|
| Cohort Studies | 10 | 2021 | 9477 | 0.250 |
Why?
|
| Morpholines | 3 | 2016 | 296 | 0.250 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 3 | 2010 | 37 | 0.250 |
Why?
|
| Induction Chemotherapy | 3 | 2019 | 670 | 0.250 |
Why?
|
| Polyethylene Glycols | 3 | 2024 | 654 | 0.250 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2021 | 841 | 0.250 |
Why?
|
| Killer Cells, Natural | 4 | 2020 | 966 | 0.250 |
Why?
|
| Cell Line, Tumor | 21 | 2023 | 14818 | 0.250 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 1071 | 0.250 |
Why?
|
| Apoptosis Regulatory Proteins | 5 | 2023 | 618 | 0.250 |
Why?
|
| Hydrazones | 2 | 2015 | 42 | 0.250 |
Why?
|
| Mitochondria | 4 | 2019 | 1301 | 0.240 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 248 | 0.240 |
Why?
|
| Epigenesis, Genetic | 5 | 2021 | 1445 | 0.240 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 486 | 0.240 |
Why?
|
| DNA Transposable Elements | 2 | 2016 | 252 | 0.230 |
Why?
|
| Aniline Compounds | 2 | 2019 | 206 | 0.230 |
Why?
|
| Arsenicals | 3 | 2021 | 204 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2016 | 1287 | 0.230 |
Why?
|
| Immunization, Passive | 2 | 2003 | 189 | 0.230 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 781 | 0.230 |
Why?
|
| Lymphocytosis | 2 | 2014 | 58 | 0.230 |
Why?
|
| Chlorambucil | 2 | 2022 | 26 | 0.230 |
Why?
|
| Comorbidity | 5 | 2019 | 2416 | 0.230 |
Why?
|
| Cladribine | 2 | 2024 | 253 | 0.230 |
Why?
|
| Nitrophenols | 3 | 2019 | 95 | 0.230 |
Why?
|
| Trisomy | 2 | 2015 | 240 | 0.230 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2018 | 2459 | 0.230 |
Why?
|
| Histone Deacetylases | 4 | 2015 | 364 | 0.220 |
Why?
|
| Predictive Value of Tests | 9 | 2019 | 4976 | 0.220 |
Why?
|
| Monitoring, Immunologic | 1 | 2003 | 47 | 0.220 |
Why?
|
| Leukemia, T-Cell | 3 | 2009 | 90 | 0.220 |
Why?
|
| Mycoses | 2 | 2020 | 396 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2019 | 9053 | 0.220 |
Why?
|
| Biphenyl Compounds | 3 | 2019 | 189 | 0.210 |
Why?
|
| Abnormal Karyotype | 3 | 2021 | 101 | 0.210 |
Why?
|
| Drug Therapy, Combination | 9 | 2019 | 2357 | 0.210 |
Why?
|
| Benzimidazoles | 2 | 2017 | 438 | 0.210 |
Why?
|
| Macrolides | 2 | 2019 | 65 | 0.200 |
Why?
|
| Serum Amyloid P-Component | 1 | 2022 | 31 | 0.200 |
Why?
|
| Acute Disease | 15 | 2020 | 2501 | 0.200 |
Why?
|
| Oxidative Phosphorylation | 3 | 2019 | 272 | 0.200 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2014 | 426 | 0.200 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2023 | 135 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 1649 | 0.190 |
Why?
|
| 2-Chloroadenosine | 1 | 2021 | 39 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 7 | 2016 | 3496 | 0.190 |
Why?
|
| Chromosomes, Human | 2 | 2017 | 290 | 0.190 |
Why?
|
| Safety | 3 | 2019 | 464 | 0.190 |
Why?
|
| Cells, Cultured | 12 | 2019 | 5740 | 0.190 |
Why?
|
| Burkitt Lymphoma | 3 | 2017 | 350 | 0.190 |
Why?
|
| Glycoproteins | 6 | 2009 | 788 | 0.190 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 2256 | 0.180 |
Why?
|
| CD52 Antigen | 5 | 2009 | 47 | 0.180 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 101 | 0.180 |
Why?
|
| Interleukin-8 | 1 | 2003 | 531 | 0.180 |
Why?
|
| Cell Movement | 5 | 2017 | 2484 | 0.180 |
Why?
|
| Virus Activation | 3 | 2023 | 236 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2023 | 274 | 0.180 |
Why?
|
| Daunorubicin | 2 | 2020 | 314 | 0.180 |
Why?
|
| Core Binding Factors | 1 | 2021 | 113 | 0.180 |
Why?
|
| Tretinoin | 5 | 2021 | 619 | 0.180 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 24 | 0.180 |
Why?
|
| United States | 6 | 2020 | 16006 | 0.170 |
Why?
|
| Hyperphosphatemia | 1 | 2020 | 20 | 0.170 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2017 | 121 | 0.170 |
Why?
|
| Urate Oxidase | 1 | 2020 | 43 | 0.170 |
Why?
|
| Caspase 3 | 3 | 2016 | 475 | 0.170 |
Why?
|
| Blast Crisis | 2 | 2017 | 587 | 0.170 |
Why?
|
| Spiro Compounds | 1 | 2020 | 59 | 0.170 |
Why?
|
| Interferon-alpha | 5 | 2004 | 962 | 0.170 |
Why?
|
| Wnt-5a Protein | 1 | 2019 | 46 | 0.170 |
Why?
|
| ADP-ribosyl Cyclase 1 | 5 | 2015 | 150 | 0.170 |
Why?
|
| Autoantigens | 1 | 2021 | 250 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2017 | 3621 | 0.170 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2015 | 617 | 0.170 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 418 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2019 | 607 | 0.170 |
Why?
|
| Hyperuricemia | 1 | 2020 | 48 | 0.170 |
Why?
|
| Caspases | 4 | 2016 | 683 | 0.170 |
Why?
|
| Naphthalenes | 1 | 2020 | 84 | 0.170 |
Why?
|
| Genes, p53 | 2 | 2017 | 1145 | 0.170 |
Why?
|
| Gene Expression Profiling | 10 | 2016 | 5163 | 0.170 |
Why?
|
| Epidemiologic Methods | 4 | 2017 | 252 | 0.160 |
Why?
|
| Cell- and Tissue-Based Therapy | 3 | 2020 | 381 | 0.160 |
Why?
|
| Gene Rearrangement | 3 | 2017 | 817 | 0.160 |
Why?
|
| Gene Silencing | 4 | 2024 | 827 | 0.160 |
Why?
|
| Epoxy Compounds | 1 | 2019 | 57 | 0.160 |
Why?
|
| Allopurinol | 1 | 2020 | 86 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 12 | 3 | 2015 | 198 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 405 | 0.160 |
Why?
|
| RNA, Messenger | 14 | 2019 | 6436 | 0.160 |
Why?
|
| Cell Death | 3 | 2017 | 688 | 0.160 |
Why?
|
| Anemia | 3 | 2016 | 728 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 560 | 0.160 |
Why?
|
| Proteome | 2 | 2024 | 573 | 0.160 |
Why?
|
| Cytokines | 7 | 2017 | 2825 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 2287 | 0.160 |
Why?
|
| Prospective Studies | 9 | 2023 | 13385 | 0.150 |
Why?
|
| DNA Damage | 4 | 2023 | 1987 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2023 | 1474 | 0.150 |
Why?
|
| Age Factors | 12 | 2021 | 5502 | 0.150 |
Why?
|
| Patient Selection | 5 | 2019 | 2033 | 0.150 |
Why?
|
| Clonal Evolution | 2 | 2019 | 251 | 0.150 |
Why?
|
| CD5 Antigens | 2 | 2017 | 130 | 0.150 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2018 | 56 | 0.150 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 331 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2017 | 1052 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 328 | 0.150 |
Why?
|
| Purine-Nucleoside Phosphorylase | 2 | 2010 | 51 | 0.150 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2019 | 205 | 0.150 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2017 | 23 | 0.150 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 4895 | 0.150 |
Why?
|
| Glycolysis | 2 | 2017 | 529 | 0.150 |
Why?
|
| Immune Tolerance | 3 | 2017 | 427 | 0.150 |
Why?
|
| Metaphase | 1 | 2017 | 124 | 0.150 |
Why?
|
| Hypertension | 3 | 2023 | 1610 | 0.150 |
Why?
|
| Chemokine CXCL12 | 3 | 2013 | 135 | 0.150 |
Why?
|
| Patient Safety | 3 | 2018 | 657 | 0.150 |
Why?
|
| Biomarkers | 9 | 2022 | 5086 | 0.150 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2021 | 285 | 0.150 |
Why?
|
| Interleukin-15 | 2 | 2017 | 189 | 0.150 |
Why?
|
| Deoxyadenosines | 1 | 2017 | 43 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2016 | 437 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2023 | 787 | 0.140 |
Why?
|
| Immunosuppressive Agents | 3 | 2018 | 1440 | 0.140 |
Why?
|
| Incidence | 8 | 2024 | 5848 | 0.140 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2018 | 288 | 0.140 |
Why?
|
| Deprescriptions | 1 | 2017 | 25 | 0.140 |
Why?
|
| Exotoxins | 1 | 2017 | 76 | 0.140 |
Why?
|
| Herpesvirus 4, Human | 3 | 2023 | 959 | 0.140 |
Why?
|
| Calreticulin | 1 | 2017 | 87 | 0.140 |
Why?
|
| Translocation, Genetic | 3 | 2021 | 1288 | 0.140 |
Why?
|
| Chimerism | 1 | 2017 | 65 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 398 | 0.140 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 154 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2023 | 734 | 0.140 |
Why?
|
| Anemia, Aplastic | 1 | 2018 | 233 | 0.140 |
Why?
|
| Immunoglobulin D | 1 | 2016 | 17 | 0.140 |
Why?
|
| Graft vs Host Disease | 4 | 2022 | 2809 | 0.140 |
Why?
|
| Oligopeptides | 2 | 2016 | 448 | 0.140 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 179 | 0.140 |
Why?
|
| Cytodiagnosis | 1 | 2017 | 226 | 0.140 |
Why?
|
| Casein Kinase II | 1 | 2017 | 62 | 0.140 |
Why?
|
| Phosphorylation | 9 | 2017 | 4976 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2018 | 686 | 0.140 |
Why?
|
| Cell Communication | 4 | 2017 | 519 | 0.140 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2016 | 29 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2018 | 832 | 0.140 |
Why?
|
| Caveolin 1 | 1 | 2017 | 206 | 0.130 |
Why?
|
| Lymph Nodes | 4 | 2020 | 3079 | 0.130 |
Why?
|
| Lymphoma | 5 | 2017 | 1524 | 0.130 |
Why?
|
| Proteins | 3 | 2023 | 2050 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2023 | 1713 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 3 | 2011 | 161 | 0.130 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2012 | 316 | 0.130 |
Why?
|
| Mice | 16 | 2024 | 35697 | 0.130 |
Why?
|
| Case-Control Studies | 5 | 2015 | 6234 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 504 | 0.130 |
Why?
|
| Pyrimidinones | 2 | 2010 | 318 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 432 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 229 | 0.130 |
Why?
|
| Receptors, CXCR4 | 2 | 2009 | 279 | 0.130 |
Why?
|
| Pneumonia | 4 | 2020 | 798 | 0.130 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2015 | 26 | 0.130 |
Why?
|
| Transcriptome | 1 | 2024 | 1953 | 0.130 |
Why?
|
| Yttrium Radioisotopes | 2 | 2009 | 210 | 0.130 |
Why?
|
| Clinical Decision-Making | 2 | 2016 | 534 | 0.130 |
Why?
|
| Leukemia, Lymphoid | 2 | 2006 | 289 | 0.130 |
Why?
|
| Valproic Acid | 2 | 2007 | 274 | 0.130 |
Why?
|
| Mitochondrial Proteins | 2 | 2016 | 377 | 0.130 |
Why?
|
| Karyopherins | 1 | 2016 | 134 | 0.130 |
Why?
|
| Platelet Count | 5 | 2014 | 491 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 326 | 0.130 |
Why?
|
| Injections, Subcutaneous | 3 | 2010 | 343 | 0.130 |
Why?
|
| Risk Assessment | 7 | 2018 | 6845 | 0.120 |
Why?
|
| Caspases, Effector | 1 | 2014 | 4 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 361 | 0.120 |
Why?
|
| Receptors, CXCR5 | 2 | 2022 | 29 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2015 | 123 | 0.120 |
Why?
|
| Thymoma | 1 | 2018 | 252 | 0.120 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 67 | 0.120 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 7790 | 0.120 |
Why?
|
| Ondansetron | 1 | 2015 | 39 | 0.120 |
Why?
|
| Alleles | 3 | 2017 | 2594 | 0.120 |
Why?
|
| Up-Regulation | 4 | 2016 | 2438 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2010 | 894 | 0.120 |
Why?
|
| Liposomes | 3 | 2020 | 709 | 0.120 |
Why?
|
| Aminopyridines | 1 | 2016 | 223 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 3 | 2007 | 492 | 0.120 |
Why?
|
| Vomiting | 2 | 2015 | 361 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2016 | 191 | 0.120 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 1032 | 0.120 |
Why?
|
| Cytomegalovirus | 2 | 2007 | 497 | 0.120 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 192 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 477 | 0.120 |
Why?
|
| Animals | 19 | 2024 | 62359 | 0.120 |
Why?
|
| Nausea | 2 | 2015 | 540 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 5 | 2015 | 499 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2016 | 316 | 0.120 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2014 | 25 | 0.120 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2017 | 403 | 0.120 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 26 | 0.120 |
Why?
|
| Endothelial Cells | 3 | 2022 | 1035 | 0.120 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2012 | 376 | 0.120 |
Why?
|
| Chromosome Disorders | 2 | 2011 | 424 | 0.120 |
Why?
|
| Pyridines | 4 | 2011 | 1310 | 0.120 |
Why?
|
| Mutation, Missense | 2 | 2017 | 1193 | 0.120 |
Why?
|
| Organoplatinum Compounds | 3 | 2013 | 704 | 0.120 |
Why?
|
| Infusions, Intravenous | 8 | 2010 | 1437 | 0.110 |
Why?
|
| Adenosine Triphosphate | 4 | 2017 | 592 | 0.110 |
Why?
|
| Maintenance Chemotherapy | 1 | 2015 | 224 | 0.110 |
Why?
|
| Gene Deletion | 3 | 2016 | 1475 | 0.110 |
Why?
|
| Aptamers, Nucleotide | 1 | 2013 | 58 | 0.110 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 417 | 0.110 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 744 | 0.110 |
Why?
|
| Chronic Disease | 5 | 2023 | 1847 | 0.110 |
Why?
|
| Texas | 6 | 2018 | 6444 | 0.110 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 107 | 0.110 |
Why?
|
| Treatment Failure | 6 | 2017 | 1430 | 0.110 |
Why?
|
| Allografts | 3 | 2021 | 684 | 0.110 |
Why?
|
| Pyrroles | 2 | 2009 | 590 | 0.110 |
Why?
|
| Gene Transfer Techniques | 3 | 2000 | 804 | 0.110 |
Why?
|
| Immunological Synapses | 1 | 2012 | 31 | 0.110 |
Why?
|
| Bone Marrow Diseases | 2 | 2012 | 187 | 0.110 |
Why?
|
| NF-kappa B | 2 | 2017 | 1564 | 0.110 |
Why?
|
| Primary Myelofibrosis | 3 | 2013 | 914 | 0.110 |
Why?
|
| Pancytopenia | 1 | 2013 | 119 | 0.110 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 880 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2019 | 2034 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2018 | 622 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2017 | 1054 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2015 | 1646 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2020 | 929 | 0.100 |
Why?
|
| DNA-Binding Proteins | 4 | 2011 | 5030 | 0.100 |
Why?
|
| Propensity Score | 1 | 2016 | 773 | 0.100 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2012 | 75 | 0.100 |
Why?
|
| Purine Nucleosides | 2 | 2010 | 52 | 0.100 |
Why?
|
| Complementarity Determining Regions | 3 | 2008 | 44 | 0.100 |
Why?
|
| Radioimmunotherapy | 3 | 2014 | 128 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2013 | 235 | 0.100 |
Why?
|
| Viral Proteins | 1 | 2015 | 492 | 0.100 |
Why?
|
| Integrins | 1 | 2013 | 278 | 0.100 |
Why?
|
| Cyclohexylamines | 1 | 2012 | 17 | 0.100 |
Why?
|
| Urea | 1 | 2013 | 304 | 0.100 |
Why?
|
| Methotrexate | 4 | 2020 | 1030 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 437 | 0.100 |
Why?
|
| Proteasome Inhibitors | 2 | 2015 | 233 | 0.100 |
Why?
|
| Jurkat Cells | 4 | 2017 | 320 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 620 | 0.100 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 592 | 0.100 |
Why?
|
| Opportunistic Infections | 1 | 2013 | 237 | 0.100 |
Why?
|
| Gene Expression | 5 | 2017 | 3658 | 0.100 |
Why?
|
| Adenosine | 2 | 2022 | 300 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2012 | 2482 | 0.100 |
Why?
|
| Oxides | 3 | 2021 | 212 | 0.100 |
Why?
|
| Hydroxamic Acids | 3 | 2011 | 455 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2014 | 352 | 0.100 |
Why?
|
| Leukemic Infiltration | 1 | 2011 | 73 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 682 | 0.100 |
Why?
|
| Autophagy | 1 | 2017 | 912 | 0.090 |
Why?
|
| fas Receptor | 2 | 2010 | 198 | 0.090 |
Why?
|
| Immunologic Surveillance | 1 | 2011 | 60 | 0.090 |
Why?
|
| Serum Albumin | 2 | 2011 | 246 | 0.090 |
Why?
|
| Aspirin | 1 | 2014 | 384 | 0.090 |
Why?
|
| Transcription, Genetic | 5 | 2015 | 3347 | 0.090 |
Why?
|
| Transcription Factor AP-1 | 1 | 2012 | 250 | 0.090 |
Why?
|
| Syndrome | 4 | 2021 | 1401 | 0.090 |
Why?
|
| Primary Cell Culture | 3 | 2020 | 203 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 12032 | 0.090 |
Why?
|
| Nuclear Proteins | 3 | 2011 | 3449 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2011 | 188 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 192 | 0.090 |
Why?
|
| Endonucleases | 1 | 2011 | 184 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 315 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 2078 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 1329 | 0.090 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 119 | 0.090 |
Why?
|
| Chemokines | 1 | 2011 | 290 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 1261 | 0.090 |
Why?
|
| Harringtonines | 1 | 2010 | 93 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2013 | 321 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2024 | 1899 | 0.090 |
Why?
|
| Kinetics | 2 | 2020 | 2228 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2011 | 692 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2012 | 2325 | 0.090 |
Why?
|
| Thymidine Kinase | 1 | 2010 | 224 | 0.090 |
Why?
|
| In Vitro Techniques | 5 | 2015 | 1728 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2020 | 717 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2012 | 594 | 0.080 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2017 | 341 | 0.080 |
Why?
|
| RNA, Neoplasm | 2 | 2009 | 807 | 0.080 |
Why?
|
| 1-Phosphatidylinositol 4-Kinase | 1 | 2009 | 17 | 0.080 |
Why?
|
| Bone Marrow Examination | 1 | 2009 | 151 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2009 | 45 | 0.080 |
Why?
|
| Phenotype | 5 | 2023 | 6493 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2014 | 754 | 0.080 |
Why?
|
| Oxazines | 1 | 2009 | 41 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 2011 | 367 | 0.080 |
Why?
|
| Pilot Projects | 5 | 2018 | 2857 | 0.080 |
Why?
|
| Age of Onset | 3 | 2021 | 857 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2013 | 511 | 0.080 |
Why?
|
| Hemorrhagic Disorders | 1 | 2009 | 52 | 0.080 |
Why?
|
| Immunoblotting | 4 | 2017 | 901 | 0.080 |
Why?
|
| Recombinant Proteins | 5 | 2013 | 3038 | 0.080 |
Why?
|
| Adoptive Transfer | 3 | 2017 | 431 | 0.080 |
Why?
|
| Pentostatin | 3 | 2019 | 121 | 0.080 |
Why?
|
| Blotting, Western | 5 | 2015 | 3610 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2009 | 147 | 0.080 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 37 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2020 | 1859 | 0.080 |
Why?
|
| Lactones | 1 | 2009 | 93 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 498 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2023 | 741 | 0.080 |
Why?
|
| Mitoxantrone | 2 | 2009 | 227 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2012 | 2364 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2010 | 938 | 0.080 |
Why?
|
| Cancer Survivors | 1 | 2016 | 744 | 0.080 |
Why?
|
| RNA Polymerase II | 1 | 2009 | 184 | 0.080 |
Why?
|
| Neutrophils | 1 | 2013 | 875 | 0.080 |
Why?
|
| Isothiocyanates | 1 | 2008 | 44 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2015 | 1104 | 0.080 |
Why?
|
| Lymphocyte Transfusion | 2 | 2017 | 174 | 0.080 |
Why?
|
| Syndecan-1 | 1 | 2008 | 52 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 907 | 0.080 |
Why?
|
| Chemotaxis | 3 | 2015 | 139 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 776 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2011 | 889 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2011 | 595 | 0.070 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 53 | 0.070 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 207 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 3220 | 0.070 |
Why?
|
| HL-60 Cells | 2 | 2010 | 318 | 0.070 |
Why?
|
| Models, Theoretical | 2 | 2016 | 807 | 0.070 |
Why?
|
| Microfluidics | 1 | 2007 | 32 | 0.070 |
Why?
|
| B7-1 Antigen | 1 | 2007 | 84 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2008 | 98 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2010 | 910 | 0.070 |
Why?
|
| Ganciclovir | 1 | 2007 | 194 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2007 | 146 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 4955 | 0.070 |
Why?
|
| Cell Transformation, Viral | 1 | 2007 | 174 | 0.070 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2007 | 107 | 0.070 |
Why?
|
| Fungemia | 2 | 2006 | 119 | 0.070 |
Why?
|
| Ligase Chain Reaction | 1 | 2006 | 4 | 0.070 |
Why?
|
| Genetic Testing | 2 | 2019 | 1699 | 0.070 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 50 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 4 | 2017 | 5224 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 3 | 2014 | 101 | 0.070 |
Why?
|
| Genome, Human | 2 | 2012 | 1886 | 0.070 |
Why?
|
| Pneumococcal Vaccines | 1 | 2008 | 184 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2014 | 1861 | 0.070 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 46 | 0.070 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 3 | 2016 | 124 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 4651 | 0.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2010 | 372 | 0.070 |
Why?
|
| K562 Cells | 2 | 2017 | 345 | 0.070 |
Why?
|
| Energy Metabolism | 2 | 2019 | 995 | 0.070 |
Why?
|
| Cranial Irradiation | 2 | 2008 | 322 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 2058 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 369 | 0.070 |
Why?
|
| Cell Cycle Proteins | 3 | 2016 | 2122 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 840 | 0.070 |
Why?
|
| Acetylation | 4 | 2009 | 515 | 0.070 |
Why?
|
| Thiosemicarbazones | 1 | 2006 | 24 | 0.070 |
Why?
|
| Fatigue | 3 | 2018 | 1279 | 0.070 |
Why?
|
| Interleukin-12 | 1 | 2007 | 267 | 0.070 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 335 | 0.070 |
Why?
|
| Aftercare | 2 | 2018 | 253 | 0.070 |
Why?
|
| Transplantation Conditioning | 3 | 2022 | 2367 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 1320 | 0.070 |
Why?
|
| Neoplasms | 3 | 2022 | 15903 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2007 | 480 | 0.060 |
Why?
|
| Protein Binding | 3 | 2019 | 3497 | 0.060 |
Why?
|
| Adenoviridae | 2 | 2001 | 1495 | 0.060 |
Why?
|
| Splenic Neoplasms | 1 | 2006 | 124 | 0.060 |
Why?
|
| HeLa Cells | 4 | 2017 | 1686 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2022 | 220 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 1527 | 0.060 |
Why?
|
| Interleukin-11 | 1 | 2005 | 38 | 0.060 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2005 | 45 | 0.060 |
Why?
|
| Phenylurea Compounds | 2 | 2021 | 600 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 382 | 0.060 |
Why?
|
| Cell Adhesion | 3 | 2013 | 1035 | 0.060 |
Why?
|
| Alternative Splicing | 2 | 2011 | 612 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 706 | 0.060 |
Why?
|
| Survival | 2 | 2018 | 183 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2006 | 296 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 318 | 0.060 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 87 | 0.060 |
Why?
|
| Protein Array Analysis | 2 | 2023 | 503 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2023 | 4153 | 0.060 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2004 | 73 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5566 | 0.060 |
Why?
|
| Georgia | 1 | 2023 | 53 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 563 | 0.060 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2003 | 75 | 0.060 |
Why?
|
| Child | 6 | 2023 | 30545 | 0.060 |
Why?
|
| Discoidin Domain Receptors | 1 | 2023 | 7 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 1128 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2004 | 289 | 0.050 |
Why?
|
| Bone Marrow Purging | 1 | 2003 | 88 | 0.050 |
Why?
|
| Transfection | 2 | 2021 | 3130 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2015 | 149 | 0.050 |
Why?
|
| Historically Controlled Study | 1 | 2022 | 2 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2023 | 56 | 0.050 |
Why?
|
| Macrophages | 2 | 2020 | 1360 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2015 | 638 | 0.050 |
Why?
|
| Multigene Family | 1 | 2024 | 465 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 89 | 0.050 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2023 | 84 | 0.050 |
Why?
|
| Cytidine Deaminase | 1 | 2003 | 84 | 0.050 |
Why?
|
| Immunotoxins | 1 | 2003 | 120 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 720 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2023 | 76 | 0.050 |
Why?
|
| Embryo, Mammalian | 2 | 2017 | 751 | 0.050 |
Why?
|
| Amphotericin B | 1 | 2004 | 304 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 530 | 0.050 |
Why?
|
| Clinical Studies as Topic | 1 | 2022 | 19 | 0.050 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2003 | 86 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2003 | 133 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 2357 | 0.050 |
Why?
|
| Aminoglycosides | 2 | 2016 | 235 | 0.050 |
Why?
|
| Income | 1 | 2023 | 230 | 0.050 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2022 | 46 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 7404 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 689 | 0.050 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2006 | 461 | 0.050 |
Why?
|
| Cause of Death | 2 | 2015 | 784 | 0.050 |
Why?
|
| Sirolimus | 1 | 2006 | 837 | 0.050 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2002 | 114 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 1590 | 0.050 |
Why?
|
| Protein Stability | 1 | 2023 | 378 | 0.050 |
Why?
|
| Receptors, Fc | 2 | 2014 | 72 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2016 | 592 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2018 | 406 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 224 | 0.050 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 9 | 0.050 |
Why?
|
| Camptothecin | 1 | 2004 | 539 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2005 | 678 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 225 | 0.050 |
Why?
|
| Immunogenetics | 1 | 2000 | 18 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2014 | 480 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2021 | 102 | 0.050 |
Why?
|
| Syk Kinase | 2 | 2012 | 65 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2004 | 657 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 409 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2019 | 17039 | 0.050 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2000 | 58 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 6205 | 0.050 |
Why?
|
| Down-Regulation | 3 | 2011 | 2096 | 0.040 |
Why?
|
| Prednisone | 2 | 2017 | 1036 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2007 | 1261 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 540 | 0.040 |
Why?
|
| Indoles | 2 | 2019 | 1029 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2017 | 1659 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8626 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 157 | 0.040 |
Why?
|
| Sex Factors | 2 | 2017 | 2199 | 0.040 |
Why?
|
| Disease Management | 2 | 2016 | 1105 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 116 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4894 | 0.040 |
Why?
|
| Mitochondrial Membranes | 2 | 2010 | 58 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2008 | 4582 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-4A | 1 | 2019 | 13 | 0.040 |
Why?
|
| Retroviridae | 1 | 2020 | 373 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2020 | 355 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2015 | 737 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2017 | 683 | 0.040 |
Why?
|
| Biopsy | 2 | 2019 | 3537 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 619 | 0.040 |
Why?
|
| Quality of Life | 3 | 2018 | 4764 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 103 | 0.040 |
Why?
|
| SEER Program | 2 | 2016 | 1051 | 0.040 |
Why?
|
| Risk | 3 | 2007 | 1943 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 510 | 0.040 |
Why?
|
| Tyrosine | 2 | 2014 | 509 | 0.040 |
Why?
|
| Superoxides | 2 | 2009 | 219 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 4249 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2019 | 192 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2005 | 801 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 1820 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 405 | 0.040 |
Why?
|
| Genomics | 2 | 2023 | 2825 | 0.040 |
Why?
|
| Infant | 2 | 2019 | 13969 | 0.040 |
Why?
|
| Diarrhea | 2 | 2015 | 729 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2017 | 87 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2003 | 1372 | 0.040 |
Why?
|
| Intracellular Space | 1 | 2017 | 78 | 0.040 |
Why?
|
| Ribonucleotides | 1 | 2017 | 55 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3908 | 0.040 |
Why?
|
| Deuterium Oxide | 1 | 2017 | 23 | 0.040 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2017 | 59 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2017 | 260 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2012 | 1071 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 502 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2003 | 1631 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2017 | 5750 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2017 | 188 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2016 | 36 | 0.030 |
Why?
|
| Probability | 2 | 2012 | 885 | 0.030 |
Why?
|
| Cell Line | 2 | 2017 | 5373 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2015 | 2324 | 0.030 |
Why?
|
| Binding Sites | 2 | 2013 | 2260 | 0.030 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 16 | 0.030 |
Why?
|
| Ubiquitinated Proteins | 1 | 2016 | 9 | 0.030 |
Why?
|
| Homeostasis | 1 | 2021 | 933 | 0.030 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2016 | 38 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2018 | 274 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 126 | 0.030 |
Why?
|
| Transcription Factor CHOP | 1 | 2016 | 24 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2019 | 374 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2016 | 162 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 292 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2016 | 201 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2019 | 1258 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2010 | 1076 | 0.030 |
Why?
|
| Medical Records | 1 | 2017 | 446 | 0.030 |
Why?
|
| Karyotyping | 2 | 2010 | 1066 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 311 | 0.030 |
Why?
|
| Histones | 3 | 2007 | 1513 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 769 | 0.030 |
Why?
|
| Antioxidants | 2 | 2009 | 518 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 394 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2016 | 198 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 286 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2016 | 115 | 0.030 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 26 | 0.030 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2015 | 76 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 299 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 1483 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 800 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2000 | 1018 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 2323 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2009 | 810 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 7121 | 0.030 |
Why?
|
| Headache | 1 | 2015 | 174 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 905 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 507 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 323 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2015 | 198 | 0.030 |
Why?
|
| Erythema | 1 | 2014 | 48 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 181 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2016 | 293 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 5185 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 723 | 0.030 |
Why?
|
| Transcellular Cell Migration | 1 | 2013 | 2 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 353 | 0.030 |
Why?
|
| Plasmids | 1 | 2016 | 939 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 2572 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2019 | 1744 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 661 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 488 | 0.030 |
Why?
|
| Integrin alpha4beta1 | 1 | 2013 | 48 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2017 | 417 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2016 | 379 | 0.030 |
Why?
|
| Niacinamide | 1 | 2015 | 428 | 0.030 |
Why?
|
| Zinc | 1 | 2014 | 195 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2013 | 44 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2013 | 89 | 0.030 |
Why?
|
| North Carolina | 1 | 2013 | 82 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2014 | 249 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 125 | 0.030 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2013 | 25 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 504 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 6706 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2017 | 898 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 2008 | 1008 | 0.030 |
Why?
|
| Graft Survival | 1 | 2017 | 1090 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2003 | 3184 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 594 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 908 | 0.030 |
Why?
|
| Receptors, Antigen | 1 | 2013 | 68 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 1578 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 681 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 968 | 0.030 |
Why?
|
| Myeloproliferative Disorders | 1 | 2020 | 881 | 0.030 |
Why?
|
| Microvessels | 1 | 2013 | 145 | 0.030 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2011 | 10 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2015 | 729 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2011 | 70 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2016 | 1463 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 696 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 133 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 249 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 271 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2011 | 406 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2012 | 181 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2017 | 1727 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2012 | 291 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2013 | 386 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2011 | 138 | 0.020 |
Why?
|
| Cricetulus | 1 | 2011 | 213 | 0.020 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2011 | 85 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 842 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 1182 | 0.020 |
Why?
|
| CHO Cells | 1 | 2011 | 320 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 2010 | 25 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1099 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1206 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1604 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2014 | 583 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 42 | 0.020 |
Why?
|
| Nucleotide Mapping | 1 | 2010 | 29 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 625 | 0.020 |
Why?
|
| Nocardia Infections | 1 | 2010 | 36 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2014 | 957 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2010 | 74 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2010 | 77 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 541 | 0.020 |
Why?
|
| Cricetinae | 1 | 2011 | 790 | 0.020 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2010 | 39 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 158 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 202 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 3455 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 214 | 0.020 |
Why?
|
| Fever | 1 | 2012 | 516 | 0.020 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2009 | 47 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 101 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 2659 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 397 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2009 | 60 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 4061 | 0.020 |
Why?
|
| Chromones | 1 | 2009 | 121 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2009 | 114 | 0.020 |
Why?
|
| Actin Cytoskeleton | 1 | 2009 | 78 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2009 | 129 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2008 | 69 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 128 | 0.020 |
Why?
|
| Furans | 1 | 2009 | 103 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2008 | 24 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2008 | 21 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 231 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 767 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2008 | 63 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 117 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2008 | 135 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2008 | 88 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2008 | 95 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 257 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2008 | 94 | 0.020 |
Why?
|
| Mercaptopurine | 1 | 2008 | 131 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2008 | 69 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 912 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 2203 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 824 | 0.020 |
Why?
|
| Calpain | 1 | 2008 | 70 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 177 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 580 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 269 | 0.020 |
Why?
|
| Dipeptides | 1 | 2008 | 97 | 0.020 |
Why?
|
| Flavonoids | 1 | 2009 | 201 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 248 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2007 | 49 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 1831 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2008 | 137 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2007 | 123 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 614 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 157 | 0.020 |
Why?
|
| Ferritins | 1 | 2007 | 155 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2008 | 247 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2009 | 355 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 544 | 0.020 |
Why?
|
| Base Sequence | 2 | 2004 | 5453 | 0.020 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2006 | 18 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 4965 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2006 | 79 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 276 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2009 | 655 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2007 | 316 | 0.020 |
Why?
|
| Endocytosis | 1 | 2007 | 238 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 467 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 579 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 135 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2006 | 139 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 375 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 296 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 1265 | 0.020 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2005 | 22 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2005 | 56 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 5315 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1554 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 53 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2007 | 520 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2005 | 107 | 0.020 |
Why?
|
| Splenectomy | 1 | 2006 | 168 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 989 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2006 | 295 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 878 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 168 | 0.020 |
Why?
|
| Tubulin | 1 | 2005 | 202 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 816 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2005 | 192 | 0.020 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2004 | 17 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7792 | 0.020 |
Why?
|
| Organelle Biogenesis | 1 | 2004 | 31 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 434 | 0.020 |
Why?
|
| Chromosome Inversion | 1 | 2005 | 197 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2006 | 201 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 4266 | 0.010 |
Why?
|
| Seizures | 1 | 2010 | 1051 | 0.010 |
Why?
|
| ROC Curve | 1 | 2008 | 1250 | 0.010 |
Why?
|
| Actins | 1 | 2007 | 613 | 0.010 |
Why?
|
| Constipation | 1 | 2005 | 184 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2005 | 529 | 0.010 |
Why?
|
| Microtubules | 1 | 2005 | 330 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2006 | 635 | 0.010 |
Why?
|
| Everolimus | 1 | 2006 | 438 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 241 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 591 | 0.010 |
Why?
|
| Sepsis | 1 | 2009 | 688 | 0.010 |
Why?
|
| Algorithms | 1 | 2015 | 3925 | 0.010 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 402 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 224 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2007 | 621 | 0.010 |
Why?
|
| DNA Repair | 1 | 2011 | 1911 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2003 | 253 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2003 | 231 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2007 | 1166 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2010 | 930 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2003 | 162 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2009 | 1147 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 729 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2003 | 172 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 914 | 0.010 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2004 | 320 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2004 | 238 | 0.010 |
Why?
|
| Eosinophils | 1 | 2003 | 166 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2001 | 97 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2348 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2006 | 1056 | 0.010 |
Why?
|
| Smoking | 1 | 2010 | 2549 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 2949 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 1219 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 2000 | 59 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1574 | 0.010 |
Why?
|
| Bacteremia | 1 | 2006 | 721 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2003 | 366 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 1505 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2006 | 1568 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 5870 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 519 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 2142 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 5252 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 2685 | 0.010 |
Why?
|
| Palliative Care | 1 | 2006 | 2172 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 5771 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 16221 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 5451 | 0.010 |
Why?
|